美国 · SEC FORM 4
Indivior Pharmaceuticals, Inc.
INDV · Nasdaq · CIK 0001625297 · Healthcare · Drug Manufacturers—Specialty & Generic
内部人信号
2 qualifying P purchase groups
当前 180 天评分窗口
15 同一窗口内观察到的 Form 4 交易行
3 sales · 10 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 5 additional owner(s) remain in Form 4 申报证据.
买方广度与集中度
Roles in the peak window: Chief Accounting Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-08-27 · Anderson Woodrow D.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 10,413,493
- 上期报告
- 11,172,005
- 日均成交量
- 1,980,311
- 回补天数
- 5.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | Anderson Woodrow D | 买入 (P) | Common Stock | 1,500 | USD 35.69 | USD 53,535 | SEC 申报 ↗ |
| 2026-08-05 | Anderson Woodrow D | 买入 (P) | Common Stock | 1,500 | USD 36.28 | USD 54,420 | SEC 申报 ↗ |
| 2026-03-13 | Ryan Barbara | 买入 (P) | Common Stock | 8 | USD 31.09 | USD 249 | SEC 申报 ↗ |
| 2026-03-09 | Ryan Barbara | 买入 (P) | Common Stock | 31 | USD 32.56 | USD 1,009 | SEC 申报 ↗ |
| 2026-03-06 | Kingsley Stuart A | 买入 (P) | Common Stock | 940 | USD 31.87 | USD 29,958 | SEC 申报 ↗ |
| 2026-01-05 | Wheadon David E. | 买入 (P) | Ordinary Shares | 1,771 | USD 35.39 | USD 62,676 | SEC 申报 ↗ |
| 2026-01-05 | Stejbach Mark | 买入 (P) | Ordinary Shares | 775 | USD 35.39 | USD 27,427 | SEC 申报 ↗ |
| 2026-01-05 | Ryan Barbara | 买入 (P) | Ordinary Shares | 775 | USD 35.39 | USD 27,427 | SEC 申报 ↗ |
| 2026-01-05 | NINIVAGGI DANIEL A | 买入 (P) | Ordinary Shares | 775 | USD 35.39 | USD 27,427 | SEC 申报 ↗ |
| 2026-01-05 | Humphreys Keith | 买入 (P) | Ordinary Shares | 775 | USD 35.39 | USD 27,427 | SEC 申报 ↗ |
Form 4 申报证据
48 transaction lines in the latest 365-day window; 48 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | Anderson Woodrow D | 买入 (P) | Common Stock | 1,500 | USD 35.69 | USD 53,535 | SEC 申报 ↗ |
| 2026-08-05 | Anderson Woodrow D | 买入 (P) | Common Stock | 1,500 | USD 36.28 | USD 54,420 | SEC 申报 ↗ |
| 2026-07-10 | Heidbreder Christian | 卖出 (S) | Common Stock | 18,586 | USD 41.14 | USD 764,628 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | Anderson Woodrow D | 买入 (P) | Common Stock | 1,500 | USD 35.69 | USD 53,535 | SEC 申报 ↗ |
| 2026-08-05 | Anderson Woodrow D | 买入 (P) | Common Stock | 1,500 | USD 36.28 | USD 54,420 | SEC 申报 ↗ |
| 2026-07-10 | Heidbreder Christian | 卖出 (S) | Common Stock | 18,586 | USD 41.14 | USD 764,628 | SEC 申报 ↗ |
| 2026-06-22 | Ciaffoni Joseph | 期权行权／转换 (M) | Common Stock | 1,266,903 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-22 | Ciaffoni Joseph | 代扣税 (F) | Common Stock | 612,549 | USD 38.32 | USD 23,472,878 | SEC 申报 ↗ |
| 2026-06-11 | Heidbreder Christian | 卖出 (S) | Common Stock | 18,586 | USD 38.06 | USD 707,383 | SEC 申报 ↗ |
| 2026-06-08 | Preblick Ryan | 卖出 (S) | Common Stock | 36,000 | USD 37.70 | USD 1,357,200 | SEC 申报 ↗ |
| 2026-05-13 | Wheadon David E. | 奖励／授予 (A) | Common Stock | 10,430 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Thompson Juliet | 奖励／授予 (A) | Common Stock | 6,518 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Stejbach Mark | 奖励／授予 (A) | Common Stock | 6,518 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Ryan Barbara | 奖励／授予 (A) | Common Stock | 6,518 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | NINIVAGGI DANIEL A | 奖励／授予 (A) | Common Stock | 6,518 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Kingsley Stuart A | 奖励／授予 (A) | Common Stock | 6,518 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Humphreys Keith | 奖励／授予 (A) | Common Stock | 6,518 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-12 | Thompson Juliet | 代扣税 (F) | Common Stock | 1,117 | USD 38.28 | USD 42,759 | SEC 申报 ↗ |
| 2026-03-14 | Preblick Ryan | 期权行权／转换 (M) | Common Stock | 6,302 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-14 | Preblick Ryan | 代扣税 (F) | Common Stock | 2,843 | USD 31.11 | USD 88,446 | SEC 申报 ↗ |
| 2026-03-13 | Ryan Barbara | 买入 (P) | Common Stock | 8 | USD 31.09 | USD 249 | SEC 申报 ↗ |
| 2026-03-09 | Ryan Barbara | 买入 (P) | Common Stock | 31 | USD 32.56 | USD 1,009 | SEC 申报 ↗ |
| 2026-03-06 | Kingsley Stuart A | 买入 (P) | Common Stock | 940 | USD 31.87 | USD 29,958 | SEC 申报 ↗ |
| 2026-03-03 | Preblick Ryan | 期权行权／转换 (M) | Common Stock | 86,949 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Preblick Ryan | 代扣税 (F) | Common Stock | 87,597 | USD 31.98 | USD 2,801,352 | SEC 申报 ↗ |
| 2026-03-03 | Heidbreder Christian | 期权行权／转换 (M) | Common Stock | 101,544 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Heidbreder Christian | 代扣税 (F) | Common Stock | 45,797 | USD 31.98 | USD 1,464,588 | SEC 申报 ↗ |
| 2026-03-03 | Burris Jeffrey W | 期权行权／转换 (M) | Common Stock | 79,893 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Burris Jeffrey W | 代扣税 (F) | Common Stock | 36,032 | USD 31.98 | USD 1,152,303 | SEC 申报 ↗ |
| 2026-03-03 | Anderson Woodrow D | 期权行权／转换 (M) | Common Stock | 24,310 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-03 | Anderson Woodrow D | 代扣税 (F) | Common Stock | 10,965 | USD 31.98 | USD 350,661 | SEC 申报 ↗ |
| 2026-02-10 | Preblick Ryan | 奖励／授予 (A) | Common Stock | 37,358 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-10 | Heidbreder Christian | 奖励／授予 (A) | Common Stock | 33,622 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | INDV |
| CIK | 0001625297 |
| 行业 | Healthcare |
| 细分行业 | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 48 transaction lines from 2026-01-05 to 2026-08-27 10 P purchase lines · 3 S sale lines · 35 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.